自動インスリン送達システム市場：疾患タイプ別、流通別-2025～2030年の世界予測

自動インスリン送達システム市場の2023年の市場規模は8億2,139万米ドル、2024年には9億104万米ドルに達すると予測され、2030年には15億7,949万米ドルまでCAGR 9.79％で成長すると予測されています。

自動インスリン送達システム（AID）市場は、インスリン送達を自動化することで糖尿病管理を支援する技術として拡大しています。AIDシステムは、持続グルコースモニタリング（CGM）とインスリンポンプを統合し、インスリン投与量を最適化する先進的アルゴリズムを備えています。このシステムは、手作業による血糖調節を軽減することで、1型糖尿病患者や最近では2型糖尿病患者の生活の質を向上させるために極めて重要です。その用途は主に個人的な使用に及ぶが、クリニックでの施設使用も増えています。主要成長要因は、糖尿病有病率の上昇、ウェアラブル医療機器の技術進歩、医療支出の増加などです。同市場は、AIと機械学習の技術進歩から大きな恩恵を受けており、精密医療開発のための新たな道を提供しています。この技術革新は、治療計画の個別化を強化し、患者の長期的転帰の改善をサポートすることができます。

糖尿病患者が急増している新興市場にビジネス機会があり、企業は未開拓の人口層を開拓できます。さらに、AIDシステムとスマートフォン技術やIoTプラットフォームとの統合は、遠隔患者モニタリングや遠隔医療サービスを強化するため、変革の機会となります。しかし、高コスト、規制上のハードル、サイバーセキュリティ上の懸念、発展途上国におけるAIDシステムに関する不十分な認識といった課題が成長を阻害しています。さらに、保険適用が制限されていることや、先進的糖尿病技術を管理するための訓練を受けた専門家が不足していることなどから、市場は限界に直面しています。

技術革新のためには、リアルタイムデータ分析のためのアルゴリズムの高度化、ウェアラブルデバイスの生体適合性の向上、普及拡大のための費用対効果の高いソリューションの開発に研究開発の重点を置くべきです。企業は、研究開発のための戦略的提携に投資したり、アクセシビリティを高めるためにサブスクリプションベースのモデルを模索したりすることができます。市場に関する考察によると、ダイナミックで競合情勢にあり、技術革新、パートナーシップ、規制状況が成功の鍵を握っています。技術が進化し続ける中、患者中心のアプローチを優先し、強固なサイバーセキュリティ対策に投資する企業が競争優位に立つ可能性が高いです。

市場力学：急速に進化する自動インスリン送達システム市場の主要市場洞察を公開

自動インスリン送達システム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 糖尿病有病率の上昇と啓発キャンペーンの増加
  • パイプライン化され市販された改良型AIDシステムの入手可能性
  • 臨床結果を改善するAIDシステムの開発
• 市場抑制要因
  • グルコースセンサーのキャリブレーション、センサーの耐久性、皮膚関連の問題
• 市場機会
  • 既存のインスリンポンプのアップグレードと新製品開発
  • 革新的なインスリン送達システム製造のための研究開発活動の増加
• 市場課題
  • ポンプの不正確さ、センサーの不正確さや信頼性の低さに関する懸念

ポーターのファイブフォース：自動インスリン送達システム市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：自動インスリン送達システム市場における外部からの影響の把握

外部マクロ環境要因は、自動インスリン送達システム市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：自動インスリン送達システム市場における競合情勢の把握

自動インスリン送達システム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：自動インスリン送達システム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自動インスリン送達システム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：自動インスリン送達システム市場における成功への道筋を描く

自動インスリン送達システム市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病の罹患率の上昇と啓発キャンペーンの増加
    • 改善されたパイプラインと市販のAIDシステムの可用性
    • 臨床結果の改善を伴うAIDシステムの開発
  • 抑制要因
    • グルコースセンサーの校正、センサーの耐久性、皮膚関連の問題
  • 機会
    • 既存インスリンポンプのアップグレードと新製品開発
    • 革新的なインスリン送達システムの製造に向けた研究開発活動の強化
  • 課題
    • ポンプの不正確さやセンサーの不正確さや信頼性の低さに関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 自動インスリン送達システム市場：疾患タイプ別

• イントロダクション
• 1型糖尿病
• 2型糖尿病

第7章 自動インスリン送達システム市場：流通別

• イントロダクション
• 糖尿病クリニック
• 病院薬局
• 小売薬局

第8章 南北アメリカの自動インスリン送達システム市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の自動インスリン送達システム市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの自動インスリン送達システム市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Animas Corporation
• Becton, Dickinson and Company
• Bigfoot Biomedical Inc.
• Biocon Limited
• Dexcom, Inc.
• Diabeloop S.A.
• DreaMed Diabetes Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Insulet Corporation
• Medtronic PLC
• Novo Nordisk A/S
• Sanofi S.A.
• Tandem Diabetes Care, Inc.

LIST OF FIGURES

• FIGURE 1. AUTOMATED INSULIN DELIVERY SYSTEM MARKET RESEARCH PROCESS
• FIGURE 2. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. AUTOMATED INSULIN DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AUTOMATED INSULIN DELIVERY SYSTEM MARKET DYNAMICS
• TABLE 7. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DIABETES CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 21. CANADA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 22. CANADA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 33. CHINA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CHINA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 35. INDIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 70. ITALY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ITALY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 78. POLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. POLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. QATAR AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. QATAR AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 100. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. AUTOMATED INSULIN DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

The Automated Insulin Delivery System Market was valued at USD 821.39 million in 2023, expected to reach USD 901.04 million in 2024, and is projected to grow at a CAGR of 9.79%, to USD 1,579.49 million by 2030.

The market for Automated Insulin Delivery Systems (AID) is expanding as technology aids diabetes management by automating insulin delivery. The AID system integrates continuous glucose monitoring (CGM) with insulin pumps and advanced algorithms to optimize insulin dosage. This system is crucial for enhancing the quality of life for individuals with Type 1 and increasingly, Type 2 diabetes, by mitigating manual blood glucose regulation. Its application spans personal use predominantly, but institutional use in clinics is gaining traction. Key growth factors include rising diabetes prevalence, technological advancements in wearable medical devices, and increased healthcare expenditure. The market benefits significantly from technological progress in AI and machine learning, offering novel avenues for precision medicine development. This innovation can bolster personalization in treatment plans, supporting better long-term patient outcomes.

Opportunities lie in emerging markets where diabetes incidences are surging, allowing companies to tap into untapped demographics. Additionally, the integration of AID systems with smartphone technology and IoT platforms represents a transformative opportunity, as it enhances remote patient monitoring and telehealth services. However, challenges such as high cost, regulatory hurdles, cybersecurity concerns, and inadequate awareness about AID systems in developing nations impede growth. Furthermore, the market faces limitations due to restricted insurance coverage and a lack of trained professionals to manage sophisticated diabetes tech.

For innovation, research should focus on enhancing algorithm sophistication for real-time data analytics, improving biocompatibility of wearable devices, and developing cost-effective solutions to widen adoption. Businesses could invest in strategic collaborations for R&D or explore subscription-based models to enhance accessibility. Insight into the market suggests a dynamic and competitive landscape where innovation, partnerships, and regulatory navigation are key to success. As technology continues to evolve, businesses that prioritize patient-centric approaches and invest in robust cybersecurity measures will likely hold a competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Automated Insulin Delivery System Market

The Automated Insulin Delivery System Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of diabetes coupled with increasing number of awareness campaigns
  • Availability of improved pipelined and marketed AID systems
  • Developments in AID systems with improved clinical outcomes
• Market Restraints
  • Calibration of a glucose sensor, sensor durability, skin-related issues
• Market Opportunities
  • Up-gradation of existing insulin pumps and new product developmen
  • Increasing R&D activities for the production of innovative insulin delivery systems
• Market Challenges
  • Concerns regarding pump imprecision and sensor inaccuracy or unreliability

Porter's Five Forces: A Strategic Tool for Navigating the Automated Insulin Delivery System Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Automated Insulin Delivery System Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Automated Insulin Delivery System Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Automated Insulin Delivery System Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Automated Insulin Delivery System Market

A detailed market share analysis in the Automated Insulin Delivery System Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Automated Insulin Delivery System Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Automated Insulin Delivery System Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Automated Insulin Delivery System Market

A strategic analysis of the Automated Insulin Delivery System Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Automated Insulin Delivery System Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Animas Corporation, Becton, Dickinson and Company, Bigfoot Biomedical Inc., Biocon Limited, Dexcom, Inc., Diabeloop S.A., DreaMed Diabetes Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Insulet Corporation, Medtronic PLC, Novo Nordisk A/S, Sanofi S.A., and Tandem Diabetes Care, Inc..

Market Segmentation & Coverage

This research report categorizes the Automated Insulin Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Type I Diabetes and Type II Diabetes.
• Based on Distribution, market is studied across Diabetes Clinics, Hospital Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diabetes coupled with increasing number of awareness campaigns
    • 5.1.1.2. Availability of improved pipelined and marketed AID systems
    • 5.1.1.3. Developments in AID systems with improved clinical outcomes
  • 5.1.2. Restraints
    • 5.1.2.1. Calibration of a glucose sensor, sensor durability, skin-related issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Up-gradation of existing insulin pumps and new product developmen
    • 5.1.3.2. Increasing R&D activities for the production of innovative insulin delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding pump imprecision and sensor inaccuracy or unreliability
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Automated Insulin Delivery System Market, by Disease Type

• 6.1. Introduction
• 6.2. Type I Diabetes
• 6.3. Type II Diabetes

7. Automated Insulin Delivery System Market, by Distribution

• 7.1. Introduction
• 7.2. Diabetes Clinics
• 7.3. Hospital Pharmacies
• 7.4. Retail Pharmacies

8. Americas Automated Insulin Delivery System Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Automated Insulin Delivery System Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Automated Insulin Delivery System Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Animas Corporation
• 3. Becton, Dickinson and Company
• 4. Bigfoot Biomedical Inc.
• 5. Biocon Limited
• 6. Dexcom, Inc.
• 7. Diabeloop S.A.
• 8. DreaMed Diabetes Ltd.
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche Ltd.
• 11. Insulet Corporation
• 12. Medtronic PLC
• 13. Novo Nordisk A/S
• 14. Sanofi S.A.
• 15. Tandem Diabetes Care, Inc.